Cytokinetics, Incorporated (CYTK)
- Previous Close
65.27 - Open
68.21 - Bid 64.00 x 300
- Ask 64.09 x 100
- Day's Range
61.75 - 68.44 - 52 Week Range
25.98 - 110.25 - Volume
1,837,238 - Avg. Volume
1,926,919 - Market Cap (intraday)
6.695B - Beta (5Y Monthly) 0.72
- PE Ratio (TTM)
-- - EPS (TTM)
-5.40 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
93.59
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
www.cytokinetics.comRecent News: CYTK
Performance Overview: CYTK
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYTK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYTK
Valuation Measures
Market Cap
6.83B
Enterprise Value
6.97B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
836.67
Price/Book (mrq)
--
Enterprise Value/Revenue
925.18
Enterprise Value/EBITDA
-15.25
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.66%
Return on Equity (ttm)
--
Revenue (ttm)
3.75M
Net Income Avi to Common (ttm)
-530.6M
Diluted EPS (ttm)
-5.40
Balance Sheet and Cash Flow
Total Cash (mrq)
618.96M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Research Analysis: CYTK
Company Insights: CYTK
CYTK does not have Company Insights